JP2016509864A5 - - Google Patents

Download PDF

Info

Publication number
JP2016509864A5
JP2016509864A5 JP2015562504A JP2015562504A JP2016509864A5 JP 2016509864 A5 JP2016509864 A5 JP 2016509864A5 JP 2015562504 A JP2015562504 A JP 2015562504A JP 2015562504 A JP2015562504 A JP 2015562504A JP 2016509864 A5 JP2016509864 A5 JP 2016509864A5
Authority
JP
Japan
Prior art keywords
segment
seq
virus
identity
influenza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015562504A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016509864A (ja
JP6525469B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2014/059729 external-priority patent/WO2014141125A2/en
Publication of JP2016509864A publication Critical patent/JP2016509864A/ja
Publication of JP2016509864A5 publication Critical patent/JP2016509864A5/ja
Application granted granted Critical
Publication of JP6525469B2 publication Critical patent/JP6525469B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015562504A 2013-03-13 2014-03-13 インフルエンザb型ウイルス再集合 Active JP6525469B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361779888P 2013-03-13 2013-03-13
US61/779,888 2013-03-13
PCT/IB2014/059729 WO2014141125A2 (en) 2013-03-13 2014-03-13 Influenza virus reassortment

Publications (3)

Publication Number Publication Date
JP2016509864A JP2016509864A (ja) 2016-04-04
JP2016509864A5 true JP2016509864A5 (enExample) 2017-04-20
JP6525469B2 JP6525469B2 (ja) 2019-06-05

Family

ID=50440715

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015562504A Active JP6525469B2 (ja) 2013-03-13 2014-03-13 インフルエンザb型ウイルス再集合

Country Status (13)

Country Link
US (2) US10232031B2 (enExample)
EP (1) EP2968512A2 (enExample)
JP (1) JP6525469B2 (enExample)
KR (1) KR20150130344A (enExample)
CN (2) CN111334530A (enExample)
AU (2) AU2014229255B2 (enExample)
BR (1) BR112015021880A2 (enExample)
CA (1) CA2905612A1 (enExample)
HK (1) HK1218511A1 (enExample)
IL (1) IL240936B (enExample)
MX (1) MX372963B (enExample)
SG (1) SG11201507454XA (enExample)
WO (1) WO2014141125A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102939103A (zh) 2010-03-30 2013-02-20 西奈山医学院 流感病毒疫苗及其应用
EP4241785B1 (en) 2011-09-20 2026-01-28 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
SG11201504728RA (en) 2012-12-18 2015-07-30 Icahn School Med Mount Sinai Influenza virus vaccines and uses thereof
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
US10736956B2 (en) 2015-01-23 2020-08-11 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
US11013795B2 (en) 2015-06-26 2021-05-25 Seqirus UK Limited Antigenically matched influenza vaccines
KR102790570B1 (ko) 2015-07-07 2025-04-04 세퀴러스 유케이 리미티드 인플루엔자 효능 검정
MX2018015755A (es) 2016-06-15 2019-08-29 Icahn School Med Mount Sinai Proteinas de hemaglutinina de virus de influenza y usos de las mismas.
US11254733B2 (en) 2017-04-07 2022-02-22 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
ES2991988T3 (es) 2017-10-30 2024-12-05 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica
CN108018300B (zh) 2017-11-21 2020-08-28 浙江迪福润丝生物科技有限公司 区分免疫和感染动物h7亚型禽流感疫苗株及其制备方法和应用
CA3104297A1 (en) 2018-06-21 2019-12-26 Icahn School Of Medicine At Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
US12545718B2 (en) 2019-04-24 2026-02-10 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
US11642407B2 (en) 2020-02-28 2023-05-09 Massachusetts Institute Of Technology Identification of variable influenza residues and uses thereof
CN114262694B (zh) * 2021-12-06 2023-11-03 军事科学院军事医学研究院军事兽医研究所 以B型流感病毒为载体的SARS-CoV-2疫苗候选株及其构建方法和应用
CN116063409A (zh) * 2022-09-09 2023-05-05 中山大学·深圳 一种乙型流感Mosaic重组蛋白、重组质粒及其构建方法和应用
CN118978590B (zh) * 2024-10-12 2025-01-21 北京溯本源和生物科技有限公司 一种利用重组流感病毒免疫小鼠制备杂交瘤单抗的方法及应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
WO1995011700A1 (en) 1993-10-29 1995-05-04 Pharmos Corp. Submicron emulsions as vaccine adjuvants
DE19612967A1 (de) 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
DE69937999T2 (de) 1998-06-12 2009-01-29 Avir Green Hills Biotechnology Research Development Trade Ag Interferon induzierende genetisch veränderte attenuierte viren
IT1307930B1 (it) * 1999-01-26 2001-11-29 Sinco Ricerche Spa Articoli trasparenti in resina poliestere (mg32).
PL355287A1 (en) 1999-09-24 2004-04-05 Smithkline Beecham Biologicals S.A. Intranasal influenza virus vaccine
KR100797547B1 (ko) 2000-03-03 2008-01-24 자이단호진 가가쿠오요비겟세이료호겐쿠쇼 무혈청 배양 및 부유 배양에서 사용할 수 있는 세포 및상기 세포를 사용하여 백신용 바이러스를 제조하는 방법
JP5063852B2 (ja) * 2000-09-25 2012-10-31 ポリマン サイエンティフィック イミューンバイオロジッシュ フォーシュング ゲゼルシャフト ミット ベシュレンクテル ファフツング 生ワクチン及び製造方法
WO2002024878A2 (en) 2000-09-25 2002-03-28 Bayer Aktiengesellschaft Human e3 ubiquitin protein ligase-like enzyme
GB0024089D0 (en) 2000-10-02 2000-11-15 Smithkline Beecham Biolog Novel compounds
CA2438960A1 (en) 2001-02-23 2002-09-06 Glaxosmithkline Biologicals S.A. Influenza vaccine formulations for intradermal delivery
EP2281573A3 (en) 2001-02-23 2011-12-07 GlaxoSmithKline Biologicals s.a. Influenza vaccine formulations for intradermal delivery
MY134424A (en) 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
KR20110132416A (ko) 2004-04-05 2011-12-07 화이자 프로덕츠 인코포레이티드 미세유체화된 수중유 유화액 및 백신 조성물
WO2005113756A1 (en) 2004-05-14 2005-12-01 Glaxosmithkline Biologicals S.A. Method
JP2007537760A (ja) 2004-05-20 2007-12-27 アイディー バイオメディカル コーポレイション インフルエンザワクチンを製造するためのプロセス
HUE025727T2 (en) * 2004-05-24 2016-04-28 Medimmune Llc Multi-plasmid system for producing influenza virus
DK2368975T3 (en) 2004-12-23 2015-01-05 Medimmune Llc Non-tumorigenic MDCK cell line for the propagation of viruses
EP2471552B1 (en) * 2005-03-08 2015-05-06 MedImmune, LLC Reassortant influenza viruses
FR2884255B1 (fr) 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
EP1917352A4 (en) 2005-06-21 2009-03-25 Medimmune Vaccines Inc METHODS AND COMPOSITIONS FOR EXPRESSING HETEROLOGOUS PROTEASE
US8703095B2 (en) 2005-07-07 2014-04-22 Sanofi Pasteur S.A. Immuno-adjuvant emulsion
ES2525518T3 (es) 2005-11-01 2014-12-26 Novartis Vaccines And Diagnostics Gmbh Vacunas virales derivadas de células con niveles reducidos de ADN celular residual
CN102755645A (zh) * 2005-11-04 2012-10-31 诺华疫苗和诊断有限公司 佐剂配制的包含细胞因子诱导剂的流感疫苗
JP2009514844A (ja) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル スプリットインフルエンザワクチン用のアジュバントとしての遊離水相界面活性剤を含むエマルション
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
CN1810961B (zh) * 2006-02-22 2010-05-12 中国人民解放军军事医学科学院微生物流行病研究所 一种重组流感病毒及其制备方法与应用
CA2647985C (en) * 2006-03-31 2014-12-30 Warf-Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
DK2016194T3 (en) 2006-04-19 2015-06-15 Medimmune Llc METHODS AND COMPOSITIONS FOR EXPRESSION OF VIRAL NEGATIVE SENSE RNA IN DOG CELLS
EA015817B1 (ru) 2006-10-12 2011-12-30 Глаксосмитклайн Байолоджикалс С.А. Иммуногенная композиция, содержащая адъювант в виде эмульсии "масло в воде"
PT2121011E (pt) 2006-12-06 2014-07-31 Novartis Ag Vacinas compreendendo um antigénio a partir de quatro estirpes do vírus da gripe
EP2045323A1 (en) 2007-10-05 2009-04-08 Avir Green Hills Biotechnology Research Development Trade Ag Linear expression constructs for production of influenza virus particles
RU2523587C2 (ru) 2008-07-11 2014-07-20 МЕДИММЬЮН, ЭлЭлСи Варианты гемагглютинина и нейрамидазы вируса гриппа
CN107365751B (zh) * 2008-12-16 2021-07-09 纳米医疗公司 流感疫苗的生产
EA021009B1 (ru) 2009-05-21 2015-03-31 Новартис Аг ОБРАТНАЯ ГЕНЕТИКА С ИСПОЛЬЗОВАНИЕМ НЕЭНДОГЕННЫХ ПРОМОТОРОВ pol I
CN104862335A (zh) 2009-07-31 2015-08-26 诺华股份有限公司 反向遗传系统
CA2778332A1 (en) 2009-10-20 2011-04-28 Novartis Ag Improved reverse genetics methods for virus rescue
CN103025350A (zh) 2010-05-21 2013-04-03 诺华有限公司 流感病毒的重配方法

Similar Documents

Publication Publication Date Title
JP2016509864A5 (enExample)
JP2015119730A5 (enExample)
JP2016521553A5 (enExample)
JP2016501020A5 (enExample)
Milián et al. Current and emerging cell culture manufacturing technologies for influenza vaccines
Cauldwell et al. Viral determinants of influenza A virus host range
Horimoto et al. Enhanced growth of seed viruses for H5N1 influenza vaccines
JP2019011344A5 (enExample)
Petiot et al. Influenza viruses production: Evaluation of a novel avian cell line DuckCelt®-T17
WO2008156681A2 (en) Adenoviral vectors for influenza virus production
JP2017189179A5 (enExample)
JP2018064493A (ja) Mdck細胞を用いたインフルエンザウイルスの増殖方法
Li et al. Screening of the high yield influenza B virus on MDCK cell and cloning of its whole genome
Van Wielink et al. Adaptation of a Madin–Darby canine kidney cell line to suspension growth in serum-free media and comparison of its ability to produce avian influenza virus to Vero and BHK21 cell lines
Minor et al. Current challenges in implementing cell-derived influenza vaccines: implications for production and regulation, July 2007, NIBSC, Potters Bar, UK
Chen et al. Partial and full PCR-based reverse genetics strategy for influenza viruses
Mostafa et al. The PB1 segment of an influenza A virus H1N1 2009pdm isolate enhances the replication efficiency of specific influenza vaccine strains in cell culture and embryonated eggs
Johnson et al. Identification of influenza A/PR/8/34 donor viruses imparting high hemagglutinin yields to candidate vaccine viruses in eggs
US11883483B2 (en) Method for preparing influenza working virus seed stock, method for preparing influenza vaccine using same seed stock, and virus seed stock prepared by same method
Shao et al. An efficient and rapid influenza gene cloning strategy for reverse genetics system
CN104195154A (zh) 新城疫病毒Mukteswar中等毒力疫苗株反向遗传操作系统及其应用
Zhou et al. High-yield production of a stable Vero cell-based vaccine candidate against the highly pathogenic avian influenza virus H5N1
Koudstaal et al. Suitability of PER. C6® cells to generate epidemic and pandemic influenza vaccine strains by reverse genetics
Suzuki et al. Development of an influenza A master virus for generating high-growth reassortants for A/Anhui/1/2013 (H7N9) vaccine production in qualified MDCK cells
CA2880409A1 (en) Production of infectious influenza viruses